ProCE Banner Activity

Experts Discuss Key Questions in the Contemporary Management of Myelofibrosis

Clinical Thought

In this focused commentary, 3 experts answer questions posed at an ASCO 2024 symposium regarding the use of JAK inhibitors and emerging therapeutics in treating MF.

Released: July 23, 2024

Expiration: July 22, 2025

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Lucia Masarova

Lucia Masarova, MD

Assistant Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, GlaxoSmithKline, Incyte, Ionis, Jubilant, Karyopharm, Morphic, MorphoSys, Novartis, PharmaEssentia, Sumitomo; researcher: Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, Geron, Incyte, Ionis, Janssen, Kartos, Karyopharm, MorphoSys, Sumitomo, Telios.

Lucia Masarova, MD

Assistant Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Lucia Masarova, MD: consultant/advisor/speaker: Cogent, GlaxoSmithKline, MorphoSys, PharmaEssentia.

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD: consultant/advisor/speaker: AbbVie, Blueprint, Celgene/Bristol Myers Squibb, Cogent, Constellation/Morphosys, CTI, Galecto, Incyte, Jubliant, Kartos, Karyopharm, Pharmaessentia, Sierra Oncology/GlaxoSmithKline, Protagonist, Servier, Stemline, Sumitomo Dainippon, Zentalis; researcher: Constellation, Incyte, Ryvu, Stemline Therapeutics, Zentalis.